HLA-B

Chr 6

major histocompatibility complex, class I, B

Also known as: AS, B-4901, HLAB

HLA-B belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon 1 encodes the leader peptide, exon 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. Hundreds of HLA-B alleles have been described. [provided by RefSeq, Jul 2008]

GeneReviewsResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

UniProtStevens-Johnson syndrome
UniProtSpondyloarthropathy 1
12
Active trials
636
Pubs (1 yr)
P/LP submissions
P/LP missense
0.91
LOEUF
DN
Mechanism· predicted
📖
GeneReview available — HLA-B
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.91LOEUF
pLI 0.000
Z-score 1.85
OE 0.54 (0.330.91)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
-0.01Z-score
OE missense 1.00 (0.891.13)
196 obs / 195.6 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?0.54 (0.330.91)
00.351.4
Missense OE?1.00 (0.891.13)
00.61.4
Synonymous OE?0.98
01.21.6
LoF obs/exp: 10 / 18.6Missense obs/exp: 196 / 195.6Syn Z: 0.13

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

HLA-B · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

AutophagyGalectinsHIV Infections

Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

RECRUITING
NCT04160455Centre Hospitalier Régional d'OrléansStarted 2019-11-07
expression of a panel
Kidney Transplant

Alloreactive Memory B Lymphocytes and Anti-HLA Sensitization

RECRUITING
NCT07011238University Hospital, RouenStarted 2023-04-17
Patients meeting HLA immunization criteria
Liver DiseasesLiver CancerLiver Cirrhosis

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

RECRUITING
NCT07053488Phase PHASE1, PHASE2AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCStarted 2025-06-01
Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver
Diabetic Foot Ulcer (DFU)Venous Leg Ulcer (VLU)

Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers

RECRUITING
NCT07048054Phase PHASE1, PHASE2Nicolò BrembillaStarted 2025-07
TrophiPatch: allogeneic adipose-derived stromal cell patch
Hodgkin DiseaseNon-Hodgkin LymphomaSevere Chronic Active Epstein Barr Virus

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

ACTIVE NOT RECRUITING
NCT02287311Phase PHASE1Baylor College of MedicineStarted 2015-02
MABEL CTLsCyclophosphamideFludarabine
Scar Conditions and Fibrosis of SkinScar Quality Assessment and SafetyScar Tissue

Scar Remodeling After Burn Injury Using Allogeneic Adipose-derived Stromal Cells

RECRUITING
NCT07635875Phase PHASE1, PHASE2Rigshospitalet, DenmarkStarted 2026-04-16
Allogeneic adipose-Derived Mesenchymal Stromal CellsCryostor CS10 + Ringers Lactate
SepsisSeptic Shock

Myeloid Bias in the Bone Marrow of Septic Patients and Its Correlation With Disease Severity and Prognosis: A Single-Center, Prospective Cohort Study

NOT YET RECRUITING
NCT07667153Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyStarted 2026-07-15
Bone marrow aspirate collection
Cutaneous Squamous Cell Carcinoma (CSCC)

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

RECRUITING
NCT07064330Instituto de Investigación Biomédica de SalamancaStarted 2025-07-17
Cemiplimab
Type 1 Diabetes Mellitus

Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)

ACTIVE NOT RECRUITING
NCT03941132Phase PHASE2, PHASE3University of British ColumbiaStarted 2021-01-04
UstekinumabPlacebo
Ankylosing Spondylitis and Psoriatic Arthritis Patients

TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity

NOT YET RECRUITING
NCT07507487Phase NAAsmaa Hassan mohamed Abdel MawjoudStarted 2026-04
Detection of TNFAIP3 gene expression by real time PCR.
HIV InfectionsImmune ActivationComorbidities

The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study

ACTIVE NOT RECRUITING
NCT04087239University of ZimbabweStarted 2016-01-26
HIV
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia

Personalized NK Cell Therapy in CBT

RECRUITING
NCT02727803Phase PHASE2M.D. Anderson Cancer CenterStarted 2016-05-19
Allogeneic Natural Killer Cell Line NK-92Anti-Thymocyte GlobulinBusulfan